Loading...
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
BACKGROUND: Pazopanib is a tyrosine kinase inhibitor with antiangiogenic activity. Vascular endothelial growth factor expression is increased in SCLC and is correlated with poor prognosis. The efficacy and tolerance of second-line pazopanib in SCLC was evaluated. PATIENTS AND METHODS: Patients with...
Na minha lista:
| Udgivet i: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5520202/ https://ncbi.nlm.nih.gov/pubmed/28510571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.137 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|